日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Early experience with transcatheter ventricular septal defects closure with the KONAR-MF multifunctional occluder

使用KONAR-MF多功能封堵器进行经导管室间隔缺损封堵的早期经验

Elafifi, Abdelrahman; Kotit, Susy; Shehata, Mahmoud; Deyaa, Omar; Ramadan, Asmaa; Tawfik, Mohammad

The MATTERHORN trial: Percutaneous MitraClip vs surgical repair in heart-failure-related secondary mitral regurgitation

MATTERHORN试验:经皮MitraClip与外科手术修复治疗心力衰竭相关继发性二尖瓣反流的比较

Kotit, Susy

Rurality and race in heart failure risk: Insights from the Southern Community Cohort Study

农村地区和种族与心力衰竭风险:来自南方社区队列研究的启示

Kotit, Susy

Benefits of intravenous iron supplementation in heart failure

静脉注射铁剂补充治疗心力衰竭的益处

Kotit, Susy

SELECT: Glucagon-like peptide-1 receptor agonist in obese patients with cardiovascular disease in the absence of diabetes

选择:胰高血糖素样肽-1受体激动剂用于治疗无糖尿病的肥胖心血管疾病患者

Kotit, Susy; Sous, Marina

The Aswan Rheumatic heart disease reGIstry: rationale and preliminary results of the ARGI database

阿斯旺风湿性心脏病登记:ARGI数据库的理论基础和初步结果

Kotit, Susy; Yacoub, Magdi H

INVICTUS: Vitamin K antagonists remain the standard of care for rheumatic heart disease-associated atrial fibrillation

INVICTUS:维生素K拮抗剂仍然是治疗风湿性心脏病相关房颤的标准疗法

Kotit, Susy

EMMY: The continued expansion of clinical applications of SGLT2 inhibitors

艾美奖:SGLT2抑制剂临床应用的持续拓展

Kotit, Susy

Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations

从预先设定的钠-葡萄糖协同转运蛋白2 (SGLT2) 抑制剂治疗心力衰竭的荟萃分析中汲取的经验教训:是时候提出新的临床建议了

Kotit, Susy

Long-term outcomes from the UK Biobank on the impact of coffee on cardiovascular disease, arrhythmias, and mortality: Does the future hold coffee prescriptions?

英国生物银行关于咖啡对心血管疾病、心律失常和死亡率影响的长期研究结果:未来是否需要咖啡处方?

Susy, Kotit